Compare Expedia Group Inc (EXPE) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Expedia Group Inc trades at $275 (market cap $32.82B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Expedia Group Inc is far larger — about 3.2× Globus Medical Inc. Class A Common Stock's market cap, and Expedia Group Inc pays a 0.7% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EXPE | GMED | |
|---|---|---|
Market Cap | $32.82B | $10.25B |
Volume | 1,337,882 | 1,108,124 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $96.82 |
52-Week Low | $188.51 | $58.33 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $31.38B | $9.76B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $274.69, up 2.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 17.2, net income margin of 12.97%, and positive cash flow trends. Recent news highlights competitive threats from AI agents but also underscores Expedia's growth in B2B bookings and strategic partnerships.
The outlook for EXPE is positive, supported by earnings momentum and a consensus price target of $335.06, though risks include AI disruption and competitive pressures. Revenue growth and margin expansion present opportunities, but investor caution is warranted given mixed analyst ratings and market volatility.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
